IMRIS Inc. (IMRSQ) Stock Price & Analysis

IMRIS Inc. (IMRSQ) Healthcare & Pipeline Overview

IMRIS Inc., established in 2005, is a Canadian healthcare company specializing in advanced image-guided therapy solutions. Its flagship VISIUS Surgical Theatre integrates real-time MRI, CT, and fluoroscopy into operating rooms, enhancing precision for neurosurgical, spinal, and cardiovascular procedures. The company provides critical intraoperative visual data, positioning it as a niche leader in high-acuity medical device technology.

What Is the Investment Thesis for IMRSQ?

IMRIS Inc. operates in a specialized segment of the medical device market, focusing on intraoperative imaging solutions through its VISIUS Surgical Theatre. The company's unique value proposition lies in providing real-time MRI, CT, and fluoroscopy directly within surgical suites, which enhances precision and decision-making in complex neurosurgical, spinal, and cardiovascular procedures. This niche specialization caters to a critical demand for improved surgical outcomes and patient safety. However, the company's financial profile, marked by a -105.2% profit margin and a $0.00B market capitalization, indicates significant operational challenges. Its listing on the OTC Other tier further signals a heightened risk profile, potentially reflecting financial distress or regulatory non-compliance, necessitating rigorous due diligence. While the specialized product offers a potential competitive advantage, the company's ability to achieve operational viability and sustained profitability within the competitive medical technology landscape remains a key consideration for investors.

Based on FMP financials and quantitative analysis

IMRSQ Key Highlights

Market Capitalization: $0.00B, indicating a micro-cap or non-reporting entity status.

• Profit Margin: -105.2%, reflecting substantial net losses relative to revenue.
• Gross Margin: 34.4%, suggesting a moderate margin on product sales before operating expenses.
• Beta: 7.79, indicating extremely high volatility relative to the broader market.
• Dividend Yield: None, as the company does not currently distribute dividends to shareholders.

Who Are IMRSQ's Competitors?

IMRSQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are IMRSQ's Key Strengths?

Specialized and integrated VISIUS Surgical Theatre offers real-time intraoperative imaging (MRI, CT, fluoroscopy).

• Enhances precision and decision-making in complex neurosurgical, spinal, cerebrovascular, and cardiovascular procedures.
• Established in 2005, indicating a history of operation in the medical device sector.
• Offers recurring revenue streams through service plans and accessories.

What Are IMRSQ's Weaknesses?

Significant negative profit margin (-105.2%) indicates substantial financial losses.

• Market capitalization of $0.00B suggests a very small or distressed financial standing.
• Trading on the OTC Other tier, implying heightened risk, potential financial distress, or regulatory non-compliance.
• High Beta of 7.79, indicating extreme stock price volatility.

What Are the Key Risks for IMRSQ?

Financial-distress signal — its Altman Z-Score of -4.51 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Significant negative profit margin (-105.2%) indicating persistent operational losses and potential financial instability.
• Heightened risk profile associated with trading on the OTC Other tier, including potential financial distress or regulatory non-compliance.
• Intense competition within the medical device sector from larger, more established players with greater resources.
• Challenges in maintaining operational viability and achieving sustained profitability given the current financial metrics.
• Regulatory hurdles and compliance costs inherent in the medical device industry, potentially impacting market access or product development.

What Threats Does IMRSQ Face?

• Intense competition from larger, more diversified medical technology companies.
• Stringent and evolving regulatory approval processes for medical devices.
• Risk of technological obsolescence if innovation does not keep pace with industry advancements.
• Ongoing financial viability challenges and potential for further operational losses.

What Are IMRSQ's Competitive Advantages?

• Integrated System Design: The VISIUS Surgical Theatre offers a unique integration of multiple imaging modalities directly within the operating room, providing real-time data without patient transport.
• Specialized Niche Focus: Caters to high-acuity neurosurgical, spinal, and cardiovascular procedures, where precision and real-time feedback are paramount and competition for fully integrated solutions may be less fragmented.
• Proprietary Technology: Development and production of advanced image-guided therapy solutions likely involve proprietary hardware and software, creating barriers to entry for competitors.
• Clinical Efficacy and Precision: The system's ability to significantly boost treatment precision and aid critical decision-making provides a strong clinical value proposition for medical institutions.

What Does IMRSQ Do?

Based in Winnipeg, Canada, IMRIS Inc. was established in 2005 with a mission to revolutionize surgical procedures through advanced imaging technology. The company has since evolved into a global leader in the development, production, and distribution of sophisticated image-guided therapy solutions. At the core of its offering is the VISIUS Surgical Theatre, a highly advanced operating room environment designed to provide medical professionals with real-time, intraoperative visual data. This unique integration significantly enhances decision-making capabilities and boosts the precision of patient treatments across complex surgical interventions. The VISIUS Surgical Theatre is distinguished by its ability to seamlessly incorporate state-of-the-art imaging modalities, including magnetic resonance imaging (MRI), computed tomography (CT), and fluoroscopy, directly within multi-purpose surgical suites. This innovative approach brings diagnostic-quality imaging capabilities directly into the sterile operating field, eliminating the need to transport critically ill patients to separate imaging departments during procedures. This integration is crucial for a diverse range of medical procedures, particularly those in neurosurgical, spinal, cerebrovascular, and cardiovascular specialties, where real-time anatomical feedback can be life-saving. IMRIS Inc. primarily targets hospitals and medical centers that deliver high-acuity clinical care, providing them with comprehensive, integrated surgical environments. Beyond the initial installation of its core VISIUS systems, the company maintains ongoing relationships with its clients by offering a suite of complementary services. These include comprehensive service plans, extended maintenance agreements, and a variety of essential accessories and disposables, ensuring the long-term operational efficiency and clinical utility of its advanced surgical theatres. This business model supports both initial capital equipment sales and recurring revenue streams, solidifying IMRIS's position in the specialized medical device market.

What Products and Services Does IMRSQ Offer?

• Develops, produces, and distributes advanced image-guided therapy solutions.
• Offers the VISIUS Surgical Theatre, an integrated operating room environment.
• Provides real-time, intraoperative visual data to medical professionals during surgery.
• Integrates MRI, CT, and fluoroscopy directly into surgical suites.
• Aids critical decision-making and boosts precision in patient treatments.
• Serves neurosurgical, spinal, cerebrovascular, and cardiovascular specialties.
• Sells integrated theatres to hospitals providing clinical care.
• Provides comprehensive service plans, maintenance agreements, and accessories.

How Does IMRSQ Make Money?

• Capital Equipment Sales: Generates revenue from the sale and installation of its flagship VISIUS Surgical Theatre systems to hospitals and medical centers.
• Recurring Service Revenue: Earns ongoing income through comprehensive service plans and extended maintenance agreements for its installed base of systems.
• Accessory and Consumable Sales: Sells essential accessories and disposable components required for the operation and maintenance of its image-guided therapy solutions.

What Industry Does IMRSQ Operate In?

IMRIS Inc. operates within the highly specialized and technologically advanced medical device sector, specifically focusing on image-guided therapy solutions. This industry segment is characterized by continuous innovation, stringent regulatory requirements, and a strong emphasis on improving patient outcomes and surgical precision. The broader market for medical imaging and surgical navigation systems is driven by an aging global population, increasing prevalence of chronic diseases, and advancements in minimally invasive surgical techniques. IMRIS positions itself by integrating high-fidelity imaging modalities directly into the operating room, differentiating its VISIUS Surgical Theatre from traditional standalone imaging units. While the market for surgical equipment is competitive, IMRIS targets a niche requiring real-time intraoperative imaging for complex procedures like neurosurgery and cardiovascular interventions. This focus places it within a segment valuing advanced technology and integrated solutions, though it also faces competition from larger, more diversified medical technology companies.

Who Are IMRSQ's Key Customers?

• Hospitals and medical centers that provide high-acuity clinical care.
• Neurosurgical departments requiring real-time imaging during brain and spine procedures.
• Spinal surgery units benefiting from intraoperative guidance.
• Cerebrovascular specialists performing delicate procedures with imaging support.
• Cardiovascular surgery teams utilizing advanced imaging for heart and vessel operations.

Company Profile

IMRIS Inc. operates in the Healthcare sector. It is headquartered in Minnetonka, US. IMRSQ has traded publicly since 2023.

Key Financial Metrics

Return on assets is -46.4%, showing how much profit it generates from its asset base. A current ratio of 1.10 indicates the company holds enough short-term assets to cover its near-term obligations.

IMRIS Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.51 places it in the distress zone, a signal of elevated financial risk.

IMRIS Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 22.6% below estimates on average.

IMRSQ Financials

IMRSQ Latest News

No recent news available for IMRSQ.

IMRSQ Analyst Consensus

IMRSQ MoonshotScore

Common Questions About IMRSQ (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources